HUE054342T2 - Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére render IL-4 és/vagy IL-13 receptorához történõ kötõdésének gátlásával - Google Patents
Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére render IL-4 és/vagy IL-13 receptorához történõ kötõdésének gátlásávalInfo
- Publication number
- HUE054342T2 HUE054342T2 HUE18197286A HUE18197286A HUE054342T2 HU E054342 T2 HUE054342 T2 HU E054342T2 HU E18197286 A HUE18197286 A HU E18197286A HU E18197286 A HUE18197286 A HU E18197286A HU E054342 T2 HUE054342 T2 HU E054342T2
- Authority
- HU
- Hungary
- Prior art keywords
- preventing
- methods
- inhibiting binding
- treating certain
- certain disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161570018P | 2011-12-13 | 2011-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE054342T2 true HUE054342T2 (hu) | 2021-08-30 |
Family
ID=47552959
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE18197286A HUE054342T2 (hu) | 2011-12-13 | 2012-12-12 | Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére render IL-4 és/vagy IL-13 receptorához történõ kötõdésének gátlásával |
| HUE12813295A HUE042720T2 (hu) | 2011-12-13 | 2012-12-12 | Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révén |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE12813295A HUE042720T2 (hu) | 2011-12-13 | 2012-12-12 | Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révén |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9572863B2 (hu) |
| EP (3) | EP3842058B1 (hu) |
| JP (5) | JP6163162B2 (hu) |
| CN (2) | CN109432402B (hu) |
| AU (1) | AU2012350660B2 (hu) |
| CA (1) | CA2858962C (hu) |
| DK (2) | DK3453400T3 (hu) |
| ES (2) | ES2710384T3 (hu) |
| HU (2) | HUE054342T2 (hu) |
| PL (2) | PL2790719T3 (hu) |
| SG (2) | SG11201402992SA (hu) |
| TR (1) | TR201901826T4 (hu) |
| WO (1) | WO2013087660A1 (hu) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011154420A2 (en) * | 2010-06-08 | 2011-12-15 | Pieris Ag | Tear lipocalin muteins binding il-4 r alpha |
| CN109432402B (zh) | 2011-12-13 | 2022-04-29 | 皮里斯制药有限公司 | 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法 |
| US10774119B2 (en) * | 2014-05-22 | 2020-09-15 | Pieris Pharmaceuticals Gmbh | Specific-binding polypeptides and uses thereof |
| US10501510B2 (en) | 2015-07-15 | 2019-12-10 | Pieris Pharmaceuticals Gmbh | Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereof |
| CN107474134B (zh) * | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| CN110402252A (zh) | 2017-01-18 | 2019-11-01 | 皮里斯制药有限公司 | 对lag-3具有结合亲和力的脂质运载蛋白突变蛋白 |
| CN110770250A (zh) * | 2017-04-21 | 2020-02-07 | 金德雷德生物科学股份有限公司 | 用于兽医用途的il4/il13受体分子 |
| CN111494625B (zh) * | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物 |
| KR20210146999A (ko) | 2019-03-29 | 2021-12-06 | 피어이스 파마슈티컬즈 게엠베하 | 리포칼린 뮤테인의 흡입 투여 |
| CN113613669A (zh) * | 2019-03-29 | 2021-11-05 | 阿斯利康有限公司 | 用于治疗哮喘的脂质运载蛋白突变蛋白 |
| TW202241490A (zh) | 2020-12-18 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 用於治療氣喘之脂質運載蛋白突變蛋白乾粉配製物 |
| CN115414467B (zh) * | 2022-10-14 | 2023-06-06 | 中国人民解放军陆军军医大学第二附属医院 | 载脂蛋白d在制备治疗脑出血药物中的用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| DE4425255A1 (de) | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulierung zur inhalativen Applikation |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6446467B1 (en) | 1997-07-29 | 2002-09-10 | Physical Optics Corporation | Monolithic glass light shaping diffuser and method for its production |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| IL139786A0 (en) | 1998-06-08 | 2002-02-10 | Hoffmann La Roche | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| DE10043509A1 (de) | 2000-09-01 | 2002-03-14 | Asta Medica Ag | Feste Peptidzubereitungen für die Inhalation und deren Herstellung |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| AU2001298053A1 (en) | 2001-09-27 | 2003-04-14 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| US7238661B2 (en) * | 2002-05-24 | 2007-07-03 | Agennix, Inc. | Oral lactoferrin in the treatment of respiratory disorders |
| AU2003264100A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| RU2389796C2 (ru) | 2003-08-29 | 2010-05-20 | Аэровэнс, Инк. | Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид |
| WO2006056464A2 (en) | 2004-11-26 | 2006-06-01 | Pieris Ag | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
| AU2006294644A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| EP1996613B1 (en) | 2006-03-20 | 2014-04-30 | Technische Universität München | Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4 |
| JP5608368B2 (ja) * | 2006-08-01 | 2014-10-15 | ピエリス アーゲー | 涙リポカリンの突然変異タンパク質およびそれを得るための方法 |
| AU2008274938A1 (en) * | 2007-07-11 | 2009-01-15 | Aerovance, Inc. | Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation |
| WO2011154420A2 (en) | 2010-06-08 | 2011-12-15 | Pieris Ag | Tear lipocalin muteins binding il-4 r alpha |
| CN109432402B (zh) * | 2011-12-13 | 2022-04-29 | 皮里斯制药有限公司 | 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法 |
-
2012
- 2012-12-12 CN CN201811146540.5A patent/CN109432402B/zh active Active
- 2012-12-12 DK DK18197286.0T patent/DK3453400T3/da active
- 2012-12-12 ES ES12813295T patent/ES2710384T3/es active Active
- 2012-12-12 JP JP2014546471A patent/JP6163162B2/ja active Active
- 2012-12-12 CA CA2858962A patent/CA2858962C/en active Active
- 2012-12-12 TR TR2019/01826T patent/TR201901826T4/tr unknown
- 2012-12-12 SG SG11201402992SA patent/SG11201402992SA/en unknown
- 2012-12-12 ES ES18197286T patent/ES2863410T3/es active Active
- 2012-12-12 EP EP21152253.7A patent/EP3842058B1/en active Active
- 2012-12-12 CN CN201280061754.7A patent/CN103998053B9/zh active Active
- 2012-12-12 DK DK12813295.8T patent/DK2790719T3/en active
- 2012-12-12 SG SG10201604566QA patent/SG10201604566QA/en unknown
- 2012-12-12 HU HUE18197286A patent/HUE054342T2/hu unknown
- 2012-12-12 AU AU2012350660A patent/AU2012350660B2/en active Active
- 2012-12-12 EP EP18197286.0A patent/EP3453400B1/en active Active
- 2012-12-12 PL PL12813295T patent/PL2790719T3/pl unknown
- 2012-12-12 PL PL18197286T patent/PL3453400T3/pl unknown
- 2012-12-12 WO PCT/EP2012/075146 patent/WO2013087660A1/en active Application Filing
- 2012-12-12 EP EP12813295.8A patent/EP2790719B1/en active Active
- 2012-12-12 US US14/364,449 patent/US9572863B2/en active Active
- 2012-12-12 HU HUE12813295A patent/HUE042720T2/hu unknown
-
2016
- 2016-12-02 US US15/367,680 patent/US10016483B2/en active Active
-
2017
- 2017-03-30 JP JP2017067615A patent/JP6725447B2/ja active Active
-
2018
- 2018-06-07 US US16/002,704 patent/US10398754B2/en active Active
-
2019
- 2019-03-28 JP JP2019062186A patent/JP6889201B2/ja active Active
- 2019-07-16 US US16/513,636 patent/US10857202B2/en active Active
-
2020
- 2020-05-27 JP JP2020092168A patent/JP2020164532A/ja active Pending
- 2020-11-05 US US17/090,571 patent/US11382951B2/en active Active
-
2022
- 2022-03-25 JP JP2022049676A patent/JP7441589B2/ja active Active
- 2022-06-14 US US17/839,635 patent/US20230021168A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201604566QA (en) | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors | |
| IL288048A (en) | Methods for treating or preventing cholesterol-related disorders | |
| ZA201606957B (en) | Biguanide compositions and methods of treating metabolic disorders | |
| IL226401A0 (en) | Methods for treating disorders related to @fgfBA | |
| HK1206260A1 (en) | Compositions and methods of use for treating metabolic disorders | |
| ZA201308421B (en) | Compositions uses and methods for treatment of metabolic disorders and diseases | |
| HK1258530A1 (zh) | Serpina 1 sirnas:物質的組合物和治療方法 | |
| EP2852388A4 (en) | COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES | |
| EP2776567A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF THE CYTOMEGALIA VIRUS | |
| EP2771030A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES | |
| EP2684167A4 (en) | COMPOSITIONS AND METHODS USEFUL IN THE TREATMENT OF DISEASES | |
| PT2688557T (pt) | Métodos e composições para o tratamento de distúrbio de défice de atenção | |
| HK1198328A1 (zh) | 使用抗 抗體治療哮喘的方法和組合物 | |
| EP2691529A4 (en) | METHOD AND COMPOSITIONS FOR TREATING BRAIN DISEASES | |
| IL230433A0 (en) | Pain management methods | |
| IL232190A0 (en) | A method for treating inflammatory diseases by anti-m-csf antibodies | |
| EP2550361A4 (en) | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDER | |
| IL229705A0 (en) | Methods for the treatment or prevention of neurological diseases | |
| EP2709466A4 (en) | PROCESS FOR TREATING HONEY | |
| EP2673372A4 (en) | METHODS OF PROGNOSIS AND DELIVERY OF TREATMENT FOR INFLAMMATORY DISORDERS | |
| IL227703A0 (en) | Converted Ometic Sulfur Compounds and Methods of Using Them | |
| IL227921A0 (en) | Methods for prognosis and treatment of inflammatory disorders | |
| GB201119458D0 (en) | Compositions for treatment of sleep disorders |